Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip

Госпитализации симптомных пациентов с сердечной недостаточностью и функциональной митральной регургитацией от умеренной до тяжелой степени, которым выполнено лечение с помощью MitraClip
Gerd P Hasenfuss, Ulf Landmesser, Mark Colquhoun Petrie, José Luis Zamorano, Piotr P. Ponikowski, Alec S. Vahanian, Marco Metra, Frank Thomas Ruschitzka, Roberto Ferrari, Fausto José Pinto, Malte Kelm, Tienush Rassaf, Marianna Adamo, Stefan D. Anker, Javed Butler, John G.F. Cleland, Aldo Pietro Maggioni, Finn Gustafsson, Andreas Michael Zeiher, Mahir Karakas, Mitja Lainščak, Ottavio Alfieri, Ulrich Schäfer, Tim Friede, Muhammad Shahzeb Khan, Paul Christian Schulze, Antoni Bayés‐Genís, Angelo Auricchio, Karl‐Heinz Kück, William T. Abraham, Ralph Stephan von Bardeleben, Wojciech Wojakowski, Łukasz Wiewiórka, Wolfgang Schillinger, Gerasimos Filippatos, Evelyn Santiago‐Vacas, Friedrich Koehler, Wilhelm Haverkamp, Ilias Ninios, Vlasis N. Ninios, Monika Diek, Jutta Heinrich, Martin Geyer, Marius Placzek, Konstantinos S. Spargias, Alper Ö Öner, Nikolaos Mezilis, Efstratios K. Theofilogiannakos, Michael P. Chrissoheris, Panagiota Kourkoveli, Konstantinos G. Papadopoulos, Grzegorz A. Smolka, Krzysztof W. Reczuch, Witold Streb, Tobias Friedrich Ruf, Michael Gross, Joern Tongers
2024-08-31

RESHAPE-HF2functional mitral regurgitationheart failure hospitalizationmitral transcatheter edge-to-edge repairsymptomatic heart failure
Background For patients with functional mitral regurgitation (FMR) and symptomatic heart failure (HF), randomized trials of mitral transcatheter edge-to-edge repair (M-TEER) have produced conflicting results. Objectives This study sought to assess the impact of M-TEER on hospitalization rates, and explore the effects of M-TEER on patients who did or did not have a history of recent HF hospitalizations before undergoing M-TEER. Methods RESHAPE-HF2 (Randomized Investigation of the MitraClip Device in Heart Failure: 2nd Trial in Patients with Clinically Significant Functional Mitral Regurgitation) included patients with symptomatic HF and moderate to severe FMR (mean effective regurgitant orifice area 0.25 cm ; 14% >0.40 cm , 23% <0.20 cm ) and showed that M-TEER reduced recurrent HF hospitalizations with and without the addition of cardiovascular (CV) death and improved quality of life. We now report the results of prespecified analyses on hospitalization rates and for the subgroup of patients (n = 333) with a HF hospitalization in the 12 months before randomization. Results At 24 months, the time to first event of CV death or HF hospitalization (HR: 0.65; 95% CI: 0.49-0.85; P = 0.002), the rate of recurrent CV hospitalizations (rate ratio [RR]: 0.75; 95% CI: 0.57-0.99; P = 0.046), the composite rate of recurrent CV hospitalizations and all-cause mortality (RR: 0.74; 95% CI: 0.57-0.95; P = 0.017), and of recurrent CV death and CV hospitalizations (RR: 0.76; 95% CI: 0.58-0.99; P = 0.040), were all lower in the M-TEER group. The RR of recurrent hospitalizations for any cause was 0.82 (95% CI: 0.63-1.07; P = 0.15) for patients in the M-TEER group vs control group patients. Patients randomized to M-TEER lost fewer days due to death or HF hospitalization (13.9% [95% CI: 13.0%-14.8%] vs 17.4% [95% CI: 16.4%-18.4%] of follow-up time; P < 0.0001, and 1,067 vs 1,776 total days lost; P < 0.0001). Patients randomized to M-TEER also had better NYHA functional class at 30 days and at 6, 12, and 24 months of follow-up ( P < 0.0001). A history of HF hospitalizations before randomization was associated with worse outcomes and greater benefit with M-TEER on the rate of the composite of recurrent HF hospitalizations and CV death ( P interaction = 0.03) and of recurrent HF hospitalizations within 24 months ( P interaction = 0.06). Conclusions These results indicate that a broader application of M-TEER in addition to optimal guideline-directed medical therapy should be considered among patients with symptomatic HF and moderate to severe FMR, particularly in those with a history of a recent hospitalization for HF.
1
In RESHAPE-HF2, M-TEER reduced the 24-month risk of cardiovascular death or heart-failure hospitalization versus control (HR 0.65; P=0.002).
2
M-TEER lowered recurrent cardiovascular hospitalization rates and composites including cardiovascular hospitalization, cardiovascular death, or all-cause mortality.
3
M-TEER patients lost significantly fewer follow-up days to death or heart-failure hospitalization than controls: 13.9% versus 17.4% (P<0.0001).
4
M-TEER produced better NYHA functional class at 30 days and at 6, 12, and 24 months.
5
Reduction in recurrent hospitalizations for any cause was not statistically significant (RR 0.82; 95% CI 0.63-1.07; P=0.15).

Symptomatic heart failure patients with moderate to severe functional mitral regurgitation treated with mitral transcatheter edge-to-edge repair (M-TEER)

The effects of M-TEER on heart-failure and cardiovascular hospitalization rates, recurrent hospitalizations, mortality, lost follow-up time, and NYHA functional class

Publication Details
Publication Date
2024-08-31
Journal
Publisher
ISSN
Cited by
47
Access Type
Author Information
Authors
Gerd P Hasenfuss
Ulf Landmesser
Mark Colquhoun Petrie
José Luis Zamorano
Piotr P. Ponikowski
Alec S. Vahanian
Marco Metra
Frank Thomas Ruschitzka
Roberto Ferrari
Fausto José Pinto
Malte Kelm
Tienush Rassaf
Marianna Adamo
Stefan D. Anker
Javed Butler
John G.F. Cleland
Aldo Pietro Maggioni
Finn Gustafsson
Andreas Michael Zeiher
Mahir Karakas
Mitja Lainščak
Ottavio Alfieri
Ulrich Schäfer
Tim Friede
Muhammad Shahzeb Khan
Paul Christian Schulze
Antoni Bayés‐Genís
Angelo Auricchio
Karl‐Heinz Kück
William T. Abraham
Ralph Stephan von Bardeleben
Wojciech Wojakowski
Łukasz Wiewiórka
Wolfgang Schillinger
Gerasimos Filippatos
Evelyn Santiago‐Vacas
Friedrich Koehler
Wilhelm Haverkamp
Ilias Ninios
Vlasis N. Ninios
Monika Diek
Jutta Heinrich
Martin Geyer
Marius Placzek
Konstantinos S. Spargias
Alper Ö Öner
Nikolaos Mezilis
Efstratios K. Theofilogiannakos
Michael P. Chrissoheris
Panagiota Kourkoveli
Konstantinos G. Papadopoulos
Grzegorz A. Smolka
Krzysztof W. Reczuch
Witold Streb
Tobias Friedrich Ruf
Michael Gross
Joern Tongers
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%